RenovoRx, Inc., a biotech company based in Mountain View, California, has successfully regained compliance with the Nasdaq Stock Market LLC's minimum bid price requirement for continued listing on The Nasdaq Capital Market. The company, trading under the symbol RNXT, focuses on developing targeted oncology therapies and distributing their patented FDA-cleared drug delivery device, RenovoCath®. This recent development was announced on August 21, 2026, signifying the company's commitment to meeting market standards and maintaining its foothold in the industry.